What is the recommended management for an adult with chronic kidney disease stage 1‑4?

Management of Chronic Kidney Disease Stages 1-4

Adults with CKD stages 1-4 should be treated with SGLT2 inhibitors as the cornerstone of therapy when eGFR ≥20 ml/min per 1.73 m², combined with RAS inhibitors for those with albuminuria, to reduce progression to kidney failure and cardiovascular mortality.

Core Pharmacologic Strategy

The 2024 KDIGO guidelines establish a clear therapeutic hierarchy based on the strongest evidence for reducing morbidity and mortality 1:

1. SGLT2 Inhibitors (First-Line for Most Patients)

Initiate SGLT2i in the following scenarios:

• Strong recommendation (1A): All patients with type 2 diabetes and eGFR ≥20 ml/min per 1.73 m² 1
• Strong recommendation (1A): Any CKD patient with eGFR ≥20 ml/min per 1.73 m² AND either:
  • Urine ACR ≥200 mg/g (≥20 mg/mmol), OR
  • Heart failure (regardless of albuminuria level) 1
• Moderate recommendation (2B): Patients with eGFR 20-45 ml/min per 1.73 m² and urine ACR <200 mg/g 1

Key practice points:

• Continue SGLT2i even if eGFR drops below 20 ml/min per 1.73 m² once initiated, unless intolerance or dialysis begins 1
• Temporarily withhold during prolonged fasting, surgery, or critical illness (ketosis risk) 1
• The reversible eGFR dip after initiation is expected and not a reason to stop 1

2. RAS Inhibitors (ACEi or ARB)

Initiate based on albuminuria status:

• Strong recommendation (1B): Severely increased albuminuria (A3) without diabetes 1
• Strong recommendation (1B): Moderately-to-severely increased albuminuria (A2-A3) with diabetes 1
• Weak recommendation (2C): Moderately increased albuminuria (A2) without diabetes 1
• Consider for normal/mild albuminuria (A1) only for specific indications like hypertension or heart failure with reduced ejection fraction 1

Dosing and monitoring algorithm:

• Use maximum tolerated approved doses (trial-proven benefits achieved at these doses) 1
• Check BP, creatinine, and potassium 2-4 weeks after initiation or dose increase 1
• Continue therapy unless:
  • Creatinine rises >30% within 4 weeks 1
  • Symptomatic hypotension occurs
  • Uncontrolled hyperkalemia despite management 1
  • eGFR <15 ml/min per 1.73 m² with uremic symptoms 1
• Do NOT stop when eGFR falls below 30 ml/min per 1.73 m² 1
• Manage hyperkalemia with potassium-lowering measures rather than stopping RASi 1

3. Nonsteroidal Mineralocorticoid Receptor Antagonists (Finerenone)

Add for high-risk diabetic patients (2A recommendation):

• Type 2 diabetes with eGFR >25 ml/min per 1.73 m²
• Normal serum potassium
• Albuminuria >30 mg/g despite maximum tolerated RASi 1
• Can be combined with RASi + SGLT2i 1

Finerenone dosing protocol based on potassium:

Potassium Level	Action
≤4.8 mmol/L	Initiate: 10 mg daily if eGFR 25-59; 20 mg daily if eGFR ≥60 [1]
4.9-5.5 mmol/L	Continue current dose; monitor K+ every 4 months [1]
>5.5 mmol/L	Hold finerenone; adjust diet/medications; recheck K+; restart at 10 mg if K+ ≤5.0 [1]

• Monitor potassium at 1 month, then every 4 months 1
• Uptitrate from 10 mg to 20 mg daily when potassium remains ≤4.8 mmol/L 1

Non-Pharmacologic Management

Based on 2024 KDIGO recommendations 2:

• Diet: Mediterranean or vegetarian pattern; sodium <5 g/day; protein 0.8 g/kg/day (consider reduction in select non-diabetic patients) 2
• Physical activity: 150 minutes per week 2
• Smoking cessation (mandatory)
• Weight loss if overweight

Critical Monitoring Parameters

• eGFR and albuminuria: Regular monitoring frequency based on CKD stage
• Blood pressure target: <130/80 mmHg 3
• Proteinuria goal: <500 mg/day 3
• Avoid nephrotoxins: NSAIDs, aminoglycosides, contrast agents when possible 4

Common Pitfalls to Avoid

1. Do not discontinue RASi when creatinine rises <30% or when eGFR drops below 30 ml/min per 1.73 m² 1
2. Do not stop SGLT2i for the expected initial eGFR dip 1
3. Do not withhold RASi for hyperkalemia before attempting potassium management strategies 1
4. Do not delay SGLT2i initiation in non-diabetic CKD patients with significant albuminuria or heart failure 1
5. Do not forget to continue SGLT2i even when eGFR falls below 20 ml/min per 1.73 m² after initiation 1

Referral Threshold

Refer to nephrology for CKD stage 4-5 (eGFR <30 ml/min per 1.73 m²), rapidly progressive disease, or need for specialized interventions 5, 3.